Trial Profile
A Phase I Study of PS-341 in Combination With Paclitaxel in Metastatic Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 25 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status change from recruiting to in progress.
- 24 Aug 2005 New trial record.